I agree on the need for a larger trial. Just a small observation btw, and I may be reading too much into it, but their January PR started describing the results with “To date...” so I’m just curious if the number of patients who were treated with Nivo will increase by a few more come AACR. Would still be a small sample anyway.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.